Role of High Mobility Group Box 1 as a Prognostic Biomarker in Patients Undergoing Off-pump Coronary Artery Bypass Graft

Coronary Artery Occlusive Disease Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02206412
• Other study ID #: 4-2013-0341
• Status: Completed
• Start date: July 2014
• Est. completion date: March 16, 2017

Study information

• Verified date: July 2014
• Source: Yonsei University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

High mobility group 1 (HMGB1) protein is both a nuclear factor and a secreted protein, and has recently been identified as a cytokine mediator of systemic inflammation. HMGB1 is released by inflammatory cells actively, or increased during cell death passively and mediates inflammatory response. It has been reported to have association with the prognosis after acute coronary syndrome, ischemia-reperfusion injury of myocardium, atherosclerosis and heart failure. This study aimed to investigate the relationship of serum levels of HMGB1 and post operative prognosis of patients who had undergone off-pump coronary artery bypass graft.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 255
• Est. completion date: March 16, 2017
• Est. primary completion date: March 16, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Age = 20

2. Patients undergoing off-pump coronary artery bypass graft

Exclusion Criteria:

1. Age < 20

2. Patients undergoing off-pump coronary artery bypass graft with other simultaneous surgery

3. Patients participating other study

Related Conditions & MeSH terms

• Coronary Artery Occlusive Disease

Locations

Country	Name	City	State
Korea, Republic of	Department of Anesthesiology & Pain Medicine, Yonsei university college of medicine	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum value of HMGB1	Measure the maximum value of HMGB1 in all patients and calculate median value. And device into upper median value group and under median value group and compare frequency of composite morbidity/mortality rate between two groups. composite morbidity/mortality is as follows: Stroke; Renal failure; Prolonged ventilation more than 24 hours; Deep sternal wound infection; Reoperation for any reason; Mortality during the hospitalization for surgery, even if over 30 days	Change from induction of anesthesia to 2hrs after transfer to intensive care unit